Northland Capital analysts view MiMedx (MDXG, Financial) as significantly undervalued, suggesting that the current share price does not fully capture the company's improving business fundamentals and potential future gains. They describe the stock as "oversold," positioning it as a promising buying opportunity for investors.
The firm has reiterated its "Outperform" rating on MiMedx, affirming a target price of $12. This assessment stems from the anticipation of positive impacts from the implementation of pending Local Coverage Determinations (LCDs), which could enhance the company's valuation. The analysts believe the market has not yet recognized these potential catalysts, making MiMedx an attractive option for investors seeking growth.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for MiMedx Group Inc (MDXG, Financial) is $13.75 with a high estimate of $16.00 and a low estimate of $12.00. The average target implies an upside of 102.21% from the current price of $6.80. More detailed estimate data can be found on the MiMedx Group Inc (MDXG) Forecast page.
Based on the consensus recommendation from 5 brokerage firms, MiMedx Group Inc's (MDXG, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for MiMedx Group Inc (MDXG, Financial) in one year is $6.82, suggesting a upside of 0.29% from the current price of $6.8. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the MiMedx Group Inc (MDXG) Summary page.
